Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (CAR T) therapies for cancer. Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients. Allogeneic CAR T cell therapies are engineered from cells of healthy donors which is intended to allow for creation of inventory for “off-the-shelf” use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).